GILD - Gilead Sciences Inc. (GILD) Jefferies 2024 Global Healthcare Conference
2024-06-05 14:05:27 ET
Gilead Sciences, Inc. (GILD)
Jefferies 2024 Global Healthcare Conference
June 5, 2024 11:00 AM ET
Company Participants
Merdad Parsey - Chief Medical Officer
Conference Call Participants
Michael Yee - Jefferies
Presentation
Michael Yee
I am very happy to have up here with us Chief Medical Officer of Gilead, Merdad Parsey. It's great to have you with us fresh off of four or five days of ASCO. So lots to talk about.
Question-and-Answer Session
Q - Michael Yee
Maybe just opening up for Gilead, I'd love to just have your view of the world about where Gilead sort of R&D pipeline is today, because I would say to be fair and I'm -- not only my reports, but others, there's been a lot of commentary around the development on oncology and some of the other acquisitions oncology or not. And so people are wondering whether Gilead is on the right track on the R&D pipeline. Maybe just describe maybe the two or three key points that you see about it to be excited that maybe the Street has not seen and to address some of that sort of criticism. Thanks.
Merdad Parsey
Thanks. Thanks for having me. Great question. Thanks for opening that way, because I think that is very helpful. I do think that there's been a lot a lot of chatter. And I think from our perspective, people are kind of missing, I think the broader story, right? And for me and the way I think about it and the way I would encourage others to think about it, we are building a company, right? We're building a company and we're -- the core of our business remains our HIV business, has been and will continue to be for the foreseeable future. And I think our HIV pipeline, our current assets in our pipeline are best in the industry, and I think we're hitting on all cylinders there and I'm very, very excited about that.
Michael Yee
Definitely no criticism in HIV, yes.
Merdad Parsey
Yes. And I think people -- that's to me, I think a huge part of the bigger-picture. And then what I would add is then in oncology, we're growing. We're building. We're growing, cell therapy aside, I think we're building a portfolio and as you -- when you do so, you have some wins and losses. But overall, I think we're -- I'm very happy with the direction we're headed and we can talk about that more in a second....
Gilead Sciences, Inc. (GILD) Jefferies 2024 Global Healthcare Conference